Small molecule · Inhibitor of fibroblast activation protein (FAP) · developed by ASTRAZENECA
AZD2389 is an oral small molecule that selectively inhibits fibroblast activation protein (FAP). It is being studied in chronic liver diseases with advanced hepatic fibrosis, including cirrhosis.
Summary written with AI from the sources listed at the end of this page.
Hepatic CirrhosisLiver Fibrosis
Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →